Anebulo Pharmaceuticals

Company snapshot

Anebulo is developing innovative therapies that will improve the lives of patients suffering from acute cannabinoid intoxication and substance use disorders.

• 2 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 US patent(s) indexed to this assignee profile.
• 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Anebulo Pharmaceuticals. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Anebulo Pharmaceuticals.

1. May 23, 2026 Clinical update

   ANEB-001 — Phase 2

2. May 23, 2026 Clinical update

   selonabant — Phase 1

3. Oct 12, 2021 Patent grant

   Formulations and methods for treating acute cannabinoid overdose

View all clinical trial activity →

• What is Anebulo Pharmaceuticals?

  Anebulo Pharmaceuticals is a pharma organization headquartered in Austin, USA. It trades on NYSE under ticker ANEB. Primary therapeutic focus areas include Acute Cannabinoid Intoxication. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 1 patent record(s) to thi

• Is Anebulo Pharmaceuticals publicly traded?

  Yes. Anebulo Pharmaceuticals is listed with ticker ANEB on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Anebulo Pharmaceuticals develop or market?

  No drug profiles are currently linked to Anebulo Pharmaceuticals. Pipeline programs may still list investigational assets.

• What are the latest developments for Anebulo Pharmaceuticals?

  In the last 12 months our linked public records show 2 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Anebulo Pharmaceuticals focus on?

  Anebulo Pharmaceuticals focuses on Acute Cannabinoid Intoxication based on our analysis of their pipeline programs and drug development activities.